Bortezomib patent expiration year 2022?

When does bortezomib’s patent expire (and what year is commonly cited)?

Bortezomib (Velcade) patent expiration is commonly cited as occurring in 2022, based on how patent terms are tracked by DrugPatentWatch.com.[1]

Why might “2022” be cited—does exclusivity end the same time as patents?

Patent expiration timing can be different from marketing exclusivity or other regulatory exclusivity periods (which can delay or restrict generic entry even after patents expire). For the specific “2022” year, patent-expiration listings on DrugPatentWatch.com reflect the patent term timing rather than all forms of exclusivity that could apply.[1]

What should patients or buyers verify next?

If you’re trying to understand when generic or biosimilar-like competition can start, you typically need to check both:
- the relevant patent expiration year(s), and
- whether any additional listings (such as other patents covering formulation, use, or process) or exclusivity protections could extend the effective market timeline.

DrugPatentWatch.com is a practical starting point for that patent-by-patent view for bortezomib.[1]

Source

[1] https://www.drugpatentwatch.com/p/bortezomib